Welcome to our dedicated page for Puretech Health news (Ticker: PRTC), a resource for investors and traders seeking the latest updates and insights on Puretech Health stock.
PureTech Health plc (PRTC) generates a steady flow of news as a hub-and-spoke biotherapeutics company advancing multiple clinical-stage programs through its own R&D engine and its Founded Entities. Company announcements frequently highlight clinical data, regulatory interactions, portfolio updates, and strategic developments tied to its capital-efficient model.
Recent news releases describe PureTech’s work in idiopathic pulmonary fibrosis via deupirfenidone (LYT-100), which is being advanced toward Phase 3 development by its Founded Entity Celea Therapeutics. Updates have included Phase 2b ELEVATE IPF trial results, open-label extension data, and sub-analyses in older patient populations, as well as regulatory meetings and planning for a pivotal Phase 3 trial. These stories provide insight into how PureTech and Celea are positioning deupirfenidone as a potential new standard of care in fibrotic lung disease.
News items also cover hematologic oncology through Gallop Oncology, another PureTech Founded Entity. Gallop has reported initial topline results from a Phase 1b trial of LYT-200 in relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, including safety findings, response rates, and plans for a potentially registrational Phase 2 trial. Additional releases describe ongoing data presentations at major scientific meetings and continued maturation of survival data.
Beyond respiratory and oncology programs, PureTech’s news feed features updates from Seaport Therapeutics, such as the dosing of the first participant in a Phase 1 study of GlyphAgo (SPT-320) for generalized anxiety disorder, as well as corporate developments like leadership changes, half-year financial reports, and conference presentations including appearances at the J.P. Morgan Healthcare Conference. Investors and followers of PRTC can use this news page to track clinical milestones, strategic shifts, and the evolution of PureTech’s portfolio across its hub-and-spoke structure.
PureTech Health plc (Nasdaq: PRTC) announces a collaboration between its Founded Entity, Vor Biopharma (Nasdaq: VOR), and Janssen Biotech, Inc.. The partnership aims to explore combining Vor's engineered hematopoietic stem cell transplant platform with Janssen's bi-specific antibodies targeting acute myeloid leukemia (AML). Each company retains ownership of its respective technologies. Vor's Chief Scientific Officer expressed enthusiasm about leveraging both technologies to improve cancer treatment while minimizing side effects. This collaboration is a significant step in advancing innovative cancer therapies.
PureTech Health (PRTC) announced that its Founded Entity, Sonde Health, will collaborate with Qualcomm to enhance Sonde's vocal biomarker technology for the Snapdragon 888 and 778G 5G Mobile Platforms. This partnership aims to integrate machine learning-driven vocal biomarker capabilities into mobile and IoT devices, potentially enabling various health monitoring applications on millions of devices. Sonde’s technology can detect conditions like asthma and COVID-19 through voice analysis, paving the way for innovative, native health features directly on devices, ensuring faster and more secure health monitoring.
PureTech Health plc (Nasdaq: PRTC) has announced a clinical trial and supply agreement with BeiGene to evaluate tislelizumab, an anti-PD-1 immune checkpoint inhibitor, in combination with PureTech’s investigational monoclonal antibody LYT-200. This collaboration aims to address difficult-to-treat solid tumors. PureTech will control the LYT-200 program and expects to report topline Phase 1 results in Q4 2021. Tislelizumab is approved in China for multiple solid tumor indications, with ongoing trials aimed at expanding its use.
PureTech Health (Nasdaq: PRTC) announces that Vedanta Biosciences, its Founded Entity, presented additional results from the Phase 1 study of VE202, a 16-strain live biotherapeutic product candidate for inflammatory bowel disease (IBD) at the International Human Microbiome Consortium Congress 2021. The study showed VE202 was safe and well-tolerated with no serious adverse events. Vedanta plans to initiate a Phase 2 trial in ulcerative colitis patients, partially funded by a $25 million investment from Pfizer.
Vedanta Biosciences announced results from a Phase 1 study of VE202, a 16-strain live biotherapeutic product for inflammatory bowel disease (IBD), presented at the International Human Microbiome Consortium Congress 2021. The study showed VE202 was safe, well-tolerated, and led to durable colonization in healthy volunteers. Vedanta plans to advance VE202 to a Phase 2 trial for ulcerative colitis, funded partially by a $25 million investment from Pfizer. IBD affects approximately 3 million people in the U.S., highlighting the need for innovative treatments.
PureTech Health plc (Nasdaq: PRTC) expresses optimism following its Founded Entity, Karuna, announcing results from a Phase 1b trial of KarXT (xanomeline-trospium) in healthy elderly volunteers. The trial demonstrated that KarXT could be administered at therapeutic doses with a favorable safety and tolerability profile. Karuna plans to launch a Phase 2 trial targeting dementia-related psychosis in the first half of 2022. The majority of participants tolerated doses between 150-200 mg. PureTech holds an 8.2% stake in Karuna and is set to receive royalty payments from future net sales.
PureTech Health (Nasdaq: PRTC) has acquired the remaining 22% of shares in Alivio Therapeutics, enhancing its pipeline targeting inflammatory disorders like inflammatory bowel disease (IBD). This acquisition integrates Alivio’s technology into PureTech’s Wholly Owned Pipeline, including LYT-500, an oral treatment for IBD. This strategic move is set to be funded through partnerships and grants, aligning with PureTech's financial plan extending into Q1 2025. The transaction consists of a cash payment and future milestone payments, which are categorized as smaller transactions under listing rules.
The Annual General Meeting of PureTech Health plc (Nasdaq: PRTC) took place on May 27, 2021, with all proposed resolutions passing successfully. Key results include:
- Approval of the Annual Report for 2020: 100% votes in favor.
- Directors’ Remuneration Report: 89.74% approval.
- Directors’ Remuneration Policy: 83.90% approval.
- Election of directors Dr. Raju Kucherlapati and Dame Marjorie Scardino received 98.73% and 98.54% approval, respectively.
- Reappointment of KPMG LLP as Auditors: 99.90% approval.
These results reflect strong shareholder support for the Company's governance and financial reporting.
PureTech Health plc (Nasdaq: PRTC) noted a significant development from its Founded Entity Gelesis, which presented findings at the AACE 2021 Annual Meeting. A post-hoc analysis indicated that Plenity treatment led to a decline in the NALFD fibrosis score, a marker for liver fibrosis, compared to the placebo group. This analysis supports further trials of Plenity for metabolic-related liver diseases. Gelesis aims to enroll the first patient for a clinical study of its therapeutic candidate in NASH/NAFLD by the year's end.
PureTech Health (Nasdaq: PRTC) announced that Akili Interactive has raised $160 million through a combination of equity and debt financing. The financing includes a $110 million Series D equity round led by Neuberger Berman Funds, with participation from new and existing investors. This round brings Akili’s total equity funding to $230 million. The funds will enhance commercialization efforts for Akili's flagship product, EndeavorRx™, the first prescription video game treatment, and further support the development of digital therapeutics for cognitive disorders.